Dr. Skarbnik on the Importance of Personalized Treatment for Follicular Lymphoma

Alan P. Z. Skarbnik, MD, discusses the importance of personalizing treatment for patients with follicular lymphoma.

Alan P. Z. Skarbnik, MD, a hematologist/oncologist with Novant Health, discusses the importance of personalizing treatment for patients with follicular lymphoma.

A key challenge with follicular lymphoma is that it is a highly heterogeneous disease, both in biology and presentation. The age of patients who experience this disease and their  comorbidities are also difficult challenges to address, says Skarbnik.

As such, treatment for those with follicular lymphoma should be highly personalized and dependent on factors such as presentation and disease grade. If a biopsy is possible, patients should undergo genetic mutation testing, which is important to determine important targets and whether targeted therapy could be utilized.

It is also important to remember that not all patients require treatment, says Skarbnik. Patients can be monitored for many years on active surveillance until treatment is required. To determine whether patients will require treatment, stage, age, grade of the lymphoma, and comorbidities must be considered, adds Skarbnik.

For early-stage disease or stage I or II, which is not common and accounts for approximately 25% of patients with follicular lymphoma, there is a potential chance for a curative approach. In general, radiation therapy with or without rituximab (Rituxan) may be an option for these patients. With this approach, patients can potentially experience a very prolonged disease-free interval or even cure, concludes Skarbnik.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD